Lean Nonalcoholic Fatty Liver Disease and Sarcopenia

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 Jul 10

PMID 37424859

Authors

Milian Chen

Ying Cao

Guang Ji

Li Zhang

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases in the world. The risk factor for NAFLD is often considered to be obesity, but it can also occur in people with lean type, which is defined as lean NAFLD. Lean NAFLD is commonly associated with sarcopenia, a progressive loss of muscle quantity and quality. The pathological features of lean NAFLD such as visceral obesity, insulin resistance, and metabolic inflammation are inducers of sarcopenia, whereas loss of muscle mass and function further exacerbates ectopic fat accumulation and lean NAFLD. Therefore, we discussed the association of sarcopenia and lean NAFLD, summarized the underlying pathological mechanisms, and proposed potential strategies to reduce the risks of lean NAFLD and sarcopenia in this review.

Citing Articles

Prophylactic effects of nutrition, dietary strategies, exercise, lifestyle and environment on nonalcoholic fatty liver disease.

Hao X, Song H, Su X, Li J, Ye Y, Wang C Ann Med. 2025; 57(1):2464223.

PMID: 39943720 PMC: 11827040. DOI: 10.1080/07853890.2025.2464223.

A Novel Point-of-Care Prediction Model for Steatotic Liver Disease: Expected Role of Mass Screening in the Global Obesity Crisis.

Park J, Chung G, Chang Y, Kim S, Sohn W, Ryu S Gut Liver. 2025; 19(1):126-135.

PMID: 39778883 PMC: 11736326. DOI: 10.5009/gnl240367.

Extracellular vesicle-mediated approaches for the diagnosis and therapy of MASLD: current advances and future prospective.

Gurjar S, Bhat A R, Upadhya R, Shenoy R Lipids Health Dis. 2025; 24(1):5.

PMID: 39773634 PMC: 11705780. DOI: 10.1186/s12944-024-02396-3.

Mitigating Effects of L. on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

Mihaylova R, Gevrenova R, Petrova A, Savov Y, Zheleva-Dimitrova D, Balabanova V Plants (Basel). 2024; 13(15).

PMID: 39124206 PMC: 11314425. DOI: 10.3390/plants13152086.

Metabolic dysfunction associated fatty liver disease in healthy weight individuals.

Mendez-Sanchez N, Brouwer W, Lammert F, Yilmaz Y Hepatol Int. 2024; 18(Suppl 2):884-896.

PMID: 39052203 PMC: 11449956. DOI: 10.1007/s12072-024-10662-w.

References

Antonescu C, Foti M, Sauvonnet N, Klip A . Ready, set, internalize: mechanisms and regulation of GLUT4 endocytosis. Biosci Rep. 2009; 29(1):1-11. DOI: 10.1042/BSR20080105. View

Jung W, Kim Y, Park H . Circuit Training Improvements in Korean Women with Sarcopenia. Percept Mot Skills. 2019; 126(5):828-842. DOI: 10.1177/0031512519860637. View

Furuzono S, Kubota T, Taura J, Konishi M, Naito A, Tsutsui M . A xanthene derivative, DS20060511, attenuates glucose intolerance by inducing skeletal muscle-specific GLUT4 translocation in mice. Commun Biol. 2021; 4(1):994. PMC: 8379256. DOI: 10.1038/s42003-021-02491-6. View

Bhat N, Mani A . Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease. Nutrients. 2023; 15(10). PMC: 10222271. DOI: 10.3390/nu15102323. View

Steffl M, Bohannon R, Sontakova L, Tufano J, Shiells K, Holmerova I . Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging. 2017; 12:835-845. PMC: 5441519. DOI: 10.2147/CIA.S132940. View

Sun L, Fu J, Mu Z, Duan X, Chan P, Xiu S . Association between body fat and sarcopenia in older adults with type 2 diabetes mellitus: A cross-sectional study. Front Endocrinol (Lausanne). 2023; 14:1094075. PMC: 9911832. DOI: 10.3389/fendo.2023.1094075. View

Jiao N, Baker S, Chapa-Rodriguez A, Liu W, Nugent C, Tsompana M . Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2017; 67(10):1881-1891. DOI: 10.1136/gutjnl-2017-314307. View

Guillet C, Boirie Y . Insulin resistance: a contributing factor to age-related muscle mass loss?. Diabetes Metab. 2006; 31 Spec No 2:5S20-5S26. DOI: 10.1016/s1262-3636(05)73648-x. View

Nelson M, Madsen S, Cooke K, Fritzen A, Thorius I, Masson S . Systems-level analysis of insulin action in mouse strains provides insight into tissue- and pathway-specific interactions that drive insulin resistance. Cell Metab. 2022; 34(2):227-239.e6. DOI: 10.1016/j.cmet.2021.12.013. View

10.

Molino-Lova R, Sofi F, Pasquini G, Vannetti F, Del Ry S, Vassalle C . Higher uric acid serum levels are associated with better muscle function in the oldest old: Results from the Mugello Study. Eur J Intern Med. 2017; 41:39-43. DOI: 10.1016/j.ejim.2017.03.014. View

11.

Song N, Xu H, Wu S, Luo S, Xu J, Zhao Q . Synergistic activation of AMPK by AdipoR1/2 agonist and inhibitor of EDPs-EBP interaction recover NAFLD through enhancing mitochondrial function in mice. Acta Pharm Sin B. 2023; 13(2):542-558. PMC: 9978995. DOI: 10.1016/j.apsb.2022.10.003. View

12.

Oh S, Choi C, Lee B, Park J, Son K, Byun K . Fermented Oyster Extract Attenuated Dexamethasone-Induced Muscle Atrophy by Decreasing Oxidative Stress. Molecules. 2021; 26(23). PMC: 8658907. DOI: 10.3390/molecules26237128. View

13.

Zhai Y, Xiao Q, Miao J . The Relationship between NAFLD and Sarcopenia in Elderly Patients. Can J Gastroenterol Hepatol. 2018; 2018:5016091. PMC: 5892294. DOI: 10.1155/2018/5016091. View

14.

Orozco-Aguilar J, Tacchi F, Aguirre F, Valero-Breton M, Castro-Sepulveda M, Simon F . Ursodeoxycholic acid induces sarcopenia associated with decreased protein synthesis and autophagic flux. Biol Res. 2023; 56(1):28. PMC: 10224307. DOI: 10.1186/s40659-023-00431-8. View

15.

Spradlin R, Vassilakos G, Matheny M, Jones N, Goldman J, Lei H . Deletion of muscle exacerbates disuse atrophy weakness in mice. J Appl Physiol (1985). 2021; 131(3):881-894. PMC: 8461805. DOI: 10.1152/japplphysiol.00090.2021. View

16.

Feldman A, Eder S, Felder T, Kedenko L, Paulweber B, Stadlmayr A . Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver. Am J Gastroenterol. 2016; 112(1):102-110. DOI: 10.1038/ajg.2016.318. View

17.

Bril F, Kalavalapalli S, Clark V, Lomonaco R, Soldevila-Pico C, Liu I . Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. Clin Gastroenterol Hepatol. 2017; 16(4):558-566.e2. DOI: 10.1016/j.cgh.2017.12.001. View

18.

Ahadi M, Molooghi K, Masoudifar N, Namdar A, Vossoughinia H, Farzanehfar M . A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol. 2020; 36(6):1497-1507. DOI: 10.1111/jgh.15353. View

19.

Chung G, Kim M, Yim J, Kim J, Yoon J . Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease. J Obes Metab Syndr. 2019; 28(2):129-138. PMC: 6604841. DOI: 10.7570/jomes.2019.28.2.129. View

20.

Kim D, Wijarnpreecha K, Sandhu K, Cholankeril G, Ahmed A . Sarcopenia in nonalcoholic fatty liver disease and all-cause and cause-specific mortality in the United States. Liver Int. 2021; 41(8):1832-1840. DOI: 10.1111/liv.14852. View